Hong Kong marked a major milestone in scientific and industrial innovation with the inaugural Palladium Global Science Award, the first global award programme dedicated entirely to advancing the role of palladium in high-impact technologies. Five scientists from Canada, Japan, India, the United States, and Saudi Arabia were honoured on November 21 across three categories, sharing a combined prize fund of $350,000.The award was launched with the support of the China Precious Metals Industry Committee (CPMIC), along with contributions from Shanghai Metals Market, North-West University in South Africa, and MDX Research Center for Element Strategy in Japan. It aims to spotlight ideas that will expand palladium’s role beyond its conventional applications, particularly in catalysis, electronics, energy transition, and environmental protection.The ceremony drew leading scientists, business leaders, policymakers, and global industry partners, reaffirming the strategic importance of palladium as a metal that can accelerate decarbonisation, drive green manufacturing, and unlock new frontiers in medicine and materials science.
Sorcerer’s Servant has officially launched on Steam, marking the end of its Early Access phase and the beginning of its full release.The post Sorcerer’s Servant Has Launched Its Full Version on Steam appeared first on COGconnected.
CLINUVEL expands Singapore RD&I Centre to pioneer next-generation peptide therapiesCLINUVEL expands Singapore RD&I Centre to pioneer next-generation peptide therapiesCLINUVEL expands Singapore RD&I Centre to pioneer next-generation peptide therapiesCLINUVEL expands Singapore RD&I Centre to pioneer next-generation peptide therapiesEXECUTIVE SUMMARYVALLAURIX Research, Development & Innovation Centre to expand its existing facilities and capabilities core focus on accelerating development of liquid long-acting drug delivery platformsexisting RD&I teams will advance late-stage development programs without disruptionstrategic investment supported by the Singaporean Economic Development Board (EDB)five-year funded plan MELBOURNE, Australia and SINGAPORE, Dec. 07, 2025 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD today announced a significant expansion of its VALLAURIX Research, Development and Innovation (RD&I) Centre in Singapore. This strategic five-year investment solidifies the site’s transition into a global hub for developing advanced, long-acting peptide formulations.Supported by the Singapore Economic Development Board (EDB), the enhanced facility will integrate comprehensive formulation and analytical sciences, focusing on advancing liquid controlled-release drug products designed to optimise therapeutic outcomes for patients. This expansion is a key pillar in CLINUVEL’s strategy of vertical integration and innovation in peptide-based medicine.A Centre for Delivery InnovationThe VALLAURIX RD&I Centre is dedicated to creating novel pharmaceutical formulations that act as versatile platforms for delivering CLINUVEL’s melanocortins and other therapeutic peptides, with a focus on advanced stage programs.Since its founding in 2014, the VALLAURIX site has evolved, with the current ISO9001-certified centre opening in 2020 and receiving extensive upgrades in 2022. The new expansion will further broaden its formulation and analytical capabilities, with full commissioning and certification targeted for FY2028.Commitment to Singapore and Global GrowthCLINUVEL’s global team is spearheading the expansion, with plans to gradually increase specialist headcount in Singapore over the next five years. This growth is made possible through a strengthened economic partnership with the EDB, whose continued investment facilitates the addition of technical expertise and state-of-the-art capabilities."CLINUVEL has made a long-term investment in the VALLAURIX team and facility, which has resulted in important advancements in novel drug delivery systems,” said Dr Dennis Wright, CLINUVEL’s Chief Scientific Officer. "Our pipeline now includes platforms designed to optimise therapeutic dosing - delivering minimal, yet highly effective, levels of peptide in flexible formulations to better meet patient needs.A Future-Focused FacilityThe expansion process will ensure that ongoing projects in novel pharmaceutical and PhotoCosmetic formulation continue uninterrupted. Simultaneously, it prepares CLINUVEL to translate its research into tangible advanced therapies."We are grateful for the support from EDB and are committed to building a truly unique, bespoke facility in Singapore,” said Mr Lachlan Hay, CLINUVEL’s Chief Operating Officer. "This positions CLINUVEL at the forefront of peptide delivery technologies, enabling us to execute our vision with speed and precision."This strategic expansion underscores CLINUVEL’s commitment to leveraging Singapore’s vibrant biotech ecosystem to address complex therapeutic challenges and deliver the next wave of peptide-based medicines,” Mr Hay said.About CLINUVEL PHARMACEUTICALS LIMITEDCLINUVEL (ASX: CUV; ADR LEVEL I: CLVLY; Börse Frankfurt: UR9) is a global specialty pharmaceutical group focused on developing and commercialising treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialised populations. As pioneers in photomedicine and the family of melanocortin peptides, CLINUVEL’s research and development has led to innovative treatments for patient populations with a clinical need for systemic photoprotection, assisted DNA repair, repigmentation and acute or life-threatening conditions who lack alternatives.CLINUVEL’s lead therapy, SCENESSE® (afamelanotide 16mg), is approved for commercial distribution in Europe, the USA, Israel, and Australia as the world’s first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). Headquartered in Melbourne, Australia, CLINUVEL has operations in Europe, Singapore, and the USA. For more information, please go to https://www.clinuvel.com.Authorised for ASX release by the Board of Directors of CLINUVEL PHARMACEUTICALS LTD. Head of Investor Relations Mr Malcolm Bull, CLINUVEL PHARMACEUTICALS LTDInvestor Enquiries https://www.clinuvel.com/investors/contact-usForward-Looking Statements This release contains forward-looking statements, which reflect the current beliefs and expectations of CLINUVEL’s management. All statements other than statements of historical or current facts made in this document are forward-looking. We identify forward-looking statements in this document by using words or phrases such as "anticipate,” "believe,” "consider,” "continue,” "could,” "estimate,” "expect,” "foresee,” "intend,” "likely,” "may,” "objective,” "potential,” "plan,” "predict,” "project,” "seek,” "should,” "will” and similar words or phrases and their negatives. Forward-looking statements reflect our current expectations and are inherently uncertain. Actual outcomes or results could differ materially for a variety of reasons. Statements may involve a number of known and unknown risks that could cause our future results, performance, or achievements to differ significantly from those expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to develop and commercialise pharmaceutical products; the COVID-19 pandemic and/or other world, regional or national events affecting the supply chain for a protracted period of time, including our ability to develop, manufacture, market and sell biopharmaceutical and PhotoCosmetic products; competition for our products, especially SCENESSE® (afamelanotide 16mg), CYACÊLLE, PRÉNUMBRA®, NEURACTHEL® or products developed and characterised by us as PhotoCosmetics; our ability to achieve expected safety and efficacy results in a timely manner through our innovative R&D efforts; the effectiveness of our patents and other protections for innovative products, particularly in view of national and regional variations in patent laws; our potential exposure to product liability claims to the extent not covered by insurance; increased government scrutiny in either Australia, the U.S., Europe, the UK, Israel, China, Japan, and/or LATAM regions of our agreements with third parties and suppliers; our exposure to currency fluctuations and restrictions as well as credit risks; the effects of reforms in healthcare regulation and pharmaceutical pricing and reimbursement; that the Company may incur unexpected delays in the outsourced manufacturing of SCENESSE®, CYACÊLLE, PRÉNUMBRA®, NEURACTHEL® or products developed as PhotoCosmetics which may lead to the Company being unable to launch, supply or serve its commercial markets, special access programs and/or clinical trial programs; any failures to comply with any government payment system (i.e. Medicare, Medicaid, and U.S. Department of Veteran’s Affairs) reporting and payment obligations; uncertainties surrounding the legislative and regulatory pathways for the registration and approval of biotechnology, cosmetic and consumer based products; decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; our ability to retain or attract key personnel and managerial talent; the impact of broader change within the pharmaceutical industry, cosmetic industry and related industries; potential changes to tax liabilities or legislation; environmental risks; and other factors that have been discussed in our 2025 Annual Report. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation, outside of those required under applicable laws or relevant listing rules of the Australian Securities Exchange, to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. More information on preliminary and uncertain forecasts and estimates is available on request, whereby it is stated that past performance is not an indicator of future performance.Contact: Tel: +61 3 9660 4900 Fax: +61 3 9660 4909Email: mail@clinuvel.comPhotos accompanying this announcement are available at:https://www.globenewswire.com/NewsRoom/AttachmentNg/093c81fa-aaed-4023-b77e-1e48f45c7ef5https://www.globenewswire.com/NewsRoom/AttachmentNg/c5c6a6df-a74a-41f4-b84f-4d4466f9b5f8
SEOGWIPO, Jeju Island — Business leaders of Korea and Japan explored the idea of economic solidarity between the two countries as a paradigm aimed at addressing common challenges that their economies are facing. The Korea Chamber of Commerce and Industry (KCCI) and the Japan Chamber of Commerce and Industry (JCCI) jointly held their 14th Korea-Japan Chamber of Commerce and Industry Meeting in Seogwipo on Jeju Island, Monday. “Korea and Japan are facing common challenges at home and abroad,” KCCI Chairman Chey Tae-won said. “Externally, we must respond to the rapidly changing global trade environment and the intensifying competition in advanced technologies, while internally we are faced with structural issues such as low birthrates, aging populations and the decline of regional communities.” Noting that this year marks the 60th anniversary of the normalization of diplomatic ties between the two countries, Chey said it is time for Seoul and Tokyo to move beyond cooperation and design the future together through economic solidarity to address these challenges. “For the mutual c
Svitzer Nobbys TRAnsverse 3200Pictured: A TRAnsverse 3200 tug. Svitzer's agreement with Cochin Shipyard covers the related TRAnsverse 2600e electric tugsSVITZER BarringtonSvitzer Barrington operating in AustraliaKasper Karlsen COOKasper Karlsen, Svitzer's Chief Operating OfficerCochin, India and Copenhagen, Denmark - 8 December 2025. Svitzer, a leading global towage provider, and Cochin Shipyard Limited (CSL), India’s largest public sector shipyard, have signed a shipbuilding agreement for four 26-metre electric TRAnsverse ("TRAnsverse2600e”) tugs to be constructed in India for Svitzer’s global fleet renewal and growth plans. The agreement confirms a Letter of Intent signed in October 2025 at India Maritime Week and marks the move from intent to a contracted new build agreement. Under the agreement, CSL will build a minimum of four battery-electric TRAnsverse 2600e tugs for Svitzer, with an option for up to four additional vessels. The tugs will be constructed to Svitzer’s specifications at CSL’s facilities in Cochin to serve as global fleet renewal and advancement in operations worldwide. The vessels complement a wider newbuilding program of the TRAnsverse tug design, cementing Svitzer’s confidence in the vessel’s capabilities while also opening opportunities for future deployment in Indian ports and terminals. The deal brings together Svitzer’s global expertise in sustainable towage solutions with CSL’s proven shipbuilding capabilities, skilled workforce and local innovation. It supports India’s ambition to become a global maritime manufacturing and skills hub under Maritime India Vision 2030, Maritime Amrit Kaal Vision 2047 and the "Make in India” initiative. The TRAnsverse 2600e tugs are the electric version of the next-generation tug design proving itself as the world’s most advanced and efficient tug. The ‘Swiss Army Knife’ of tugs: the TRAnsverse design can operate in complex and close-quarter operating contexts, with all ship types and sizes in challenging weather and tidal conditions. The vessels will feature battery-electric propulsion and offer port and terminal operations zero direct emissions during harbour operations when charged from green power sources. The tug’s patented staple with double-ended hull and in-line propulsion with omni-directional thrust expands the dynamic operating envelope in towage of up to 50%. Kasper Karlsen, Chief Operating Officer, Svitzer, said: "This contract with Cochin Shipyard for our next series of electric TRAnsverse tugs reflects our commitment to Make in India and to support port and terminal operations in their green transition and decarbonisation objectives. "India has strong shipbuilding capabilities and a highly skilled workforce. Through this collaboration with CSL, we are not only investing in a series of advanced tugs for our own operations - we are also helping to build capacity for world-class, low- and zero-emission tug construction in India - signalling our trust in India’s existing capability and maritime vision. We welcome the opportunity to work closely with the CSL team to deliver these vessels and, in doing so, to support the goals of Maritime India Vision 2030 and Maritime Amrit Kaal Vision 2047 in a very practical way.” Dr Harikrishnan S, Operations Director, Cochin Shipyard Limited, said: "We look forward to delivering the next generation of tug, the TRAnsverse 2600e, drawing on CSL’s skilled workforce and our track record in complex, high‐spec vessels. This agreement represents a natural expansion of our capabilities into advanced tug design and the industrialisation of battery‐electric and future‐fuel‐ready technologies in India. The programme will deepen our expertise in electric propulsion, high‐precision manoeuvring systems and integrated digital solutions for ports and terminals, while creating opportunities for our engineers, designers and local supply chain. As a Government of India company, we remain committed to Make in India and to the decarbonisation of maritime transport. Together with Svitzer, our goal is to deliver a world‐class asset with significant decarbonisation credentials for ports in India and around the world.” The first four vessels under the agreement are expected to enter construction over the coming months, with the first delivery targeted no earlier than late 2027 / early 2028, subject to detailed design, yard scheduling and regulatory approvals. Further vessels may follow in line with Svitzer’s fleet renewal plans and customer demand. Notes to editors Number of tugs under firm order: 4 (plus options for up to 4 additional vessels) Tug design: TRAnsverse 2600E (26 m, electric) Builder: Cochin Shipyard Limited, Cochin, India Owner / operator: Svitzer Expected initial deployment regions: Northern Europe, South America, Australia Delivery timeline: first vessel targeted from late 2027 / early 2028; subsequent vessels thereafter --- About Svitzer Svitzer is a leading global towage and marine services provider. Its core business is to assist large seagoing vessels as they manoeuvre in and out of ports and terminals. With a fleet of around 450 vessels, Svitzer’s services form a critical part of port infrastructure worldwide. Founded in 1833, the company today serves approximately 2,000 customers in more than 140 ports and 40 terminals across 37 countries. Learn more at svitzer.com. About Cochin Shipyard Limited (CSL) Cochin Shipyard Limited (CSL) is India’s largest public sector shipyard by dock. Incorporated in 1972 and listed on both the BSE and NSE, CSL has established itself as a leader in shipbuilding and ship repair, capable of constructing ships up to 110,000 DWT and repairing vessels up to 125,000 DWT. The yard in Kochi has delivered some of India’s largest commercial vessels and the country’s first indigenous aircraft carrier for the Indian Navy, and is consistently rated among the top public sector undertakings in India AttachmentsSvitzer Nobbys TRAnsverse 3200SVITZER BarringtonKasper Karlsen COO
Baidu said in a filing to the Hong Kong stock exchange that media reports claiming the company plans to spin off its non-wholly owned subsidiary Kunlunxin (Beijing) Technology Co., Ltd. for an independent listing are inaccurate. The company said it is assessing a potential spin-off and listing of the unit. Any such move would be [...]
CLEVELAND (AP) — Cedric Gray isn't concerned about Tennessee Titans fans wanting the first overall NFL draft pick for the second straight year.
The government will prioritise futuristic product categories such as STEM toys, electronic and interactive toys, puzzles and board games, action figures and plu
Amazon Quiz Answers Today 8 December 2025: Participate to win Up To Rs 500 Amazon Pay Balance gadgetbridge.comAmazon Quiz Answers Today 6 December 2025: Participate to win Up To Rs 500 Amazon Pay Balance gadgetbridge.com
Mapping US Income Inequality By State The wealth of America’s top 1% sits around $52 trillion today, rising by $4 trillion over the year.Overall, the top 1% of U.S. earners need to make around $800,000 or more in salary per household. Meanwhile, about 30% of American households earned less...
WhatsApp Business could potentially start charging users who want to link more than four devices to the same account in a future update.
A bug in Google Messages is causing severe battery drain and overheating on some devices. Here's a temporary fix while you wait for Google to push an update.
Redmi 10 Power Price in India: Redmi has launched its new smartphone Redmi 10 Power in India. The smartphone was launched along with Redmi 10A, on Wednesday, 20 April in India
The premium Alienware m15 R7 and m17 R5 highlight four new Ryzen-powered systems.
Apple is offering its new firmware update for the MagSafe accessory that promises to give you faster charging for the compatible iPhone models.
System apps with native call-recording functionality remain unaffected.
The OnePlus Nord 2T India launch may take place soon as the moniker has been spotted on the TDRA certification. The OnePlus Nord 2T's camera details have also been leaked. Here are the expected specifications of the device.
The iPhone 16 is likely to be the first Apple device to skip the camera notch.
Garena Free Fire Max redeem codes are 12-digit codes that are region-specific and can be used by players to gain an edge over rivals in every round of the battle royale game.
We are still not sure that no-charger policy will be limited to Narzo 50A Prime or it will be extended to other Realme budget, mid-segment and premium phones
